|115.74||-4.64||-3.85%||Vol 1.06M||1Y Perf 152.17%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||155.47||Analyst Rating||Moderate Buy 2.09|
|Potential %||34.33||Finscreener Ranking||★★+ 48.13|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 58.36|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 51.51|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||8.73B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||41.11||Earnings Date||27th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Apr 2021|
|Estimated EPS Next Report||-1.49|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||951.62K|
|Avg. Monthly Volume||1.44M|
|Avg. Quarterly Volume||2.17M|
CRISPR Therapeutics AG (NASDAQ: CRSP) stock closed at 115.74 per share at the end of the most recent trading day (a -3.85% change compared to the prior day closing price) with a volume of 1.07M shares and market capitalization of 8.73B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 410 people. CRISPR Therapeutics AG CEO is Samarth Kulkarni.
The one-year performance of CRISPR Therapeutics AG stock is 152.17%, while year-to-date (YTD) performance is -24.41%. CRSP stock has a five-year performance of %. Its 52-week range is between 42.83 and 220.2, which gives CRSP stock a 52-week price range ratio of 41.11%
CRISPR Therapeutics AG currently has a PE ratio of -23.00, a price-to-book (PB) ratio of 5.52, a price-to-sale (PS) ratio of 16 026.60, a price to cashflow ratio of 111.30, a PEG ratio of 2.32, a ROA of -23.34%, a ROC of -20.86% and a ROE of -25.97%. The company’s profit margin is 7.42%, its EBITDA margin is -294.20%, and its revenue ttm is $562.00 Thousand , which makes it $0.01 revenue per share.
Of the last four earnings reports from CRISPR Therapeutics AG, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.49 for the next earnings report. CRISPR Therapeutics AG’s next earnings report date is 27th Apr 2021.
The consensus rating of Wall Street analysts for CRISPR Therapeutics AG is Moderate Buy (2.09), with a target price of $155.47, which is +34.33% compared to the current price. The earnings rating for CRISPR Therapeutics AG stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CRISPR Therapeutics AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CRISPR Therapeutics AG has a Sell technical analysis rating based on Technical Indicators (ADX : 23.96, ATR14 : 12.07, CCI20 : -63.73, Chaikin Money Flow : -0.02, MACD : -12.57, Money Flow Index : 34.55, ROC : -9.33, RSI : 36.58, STOCH (14,3) : 49.08, STOCH RSI : 1.00, UO : 51.28, Williams %R : -50.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CRISPR Therapeutics AG in the last 12-months were: Bradley J. Bolzon (Option Excercise at a value of $1 309 650), Bradley J. Bolzon (Sold 596 381 shares of value $77 802 321 ), James R. Kasinger (Option Excercise at a value of $1 715 969), James R. Kasinger (Sold 27 500 shares of value $5 635 943 ), Lawrence Otto Klein (Option Excercise at a value of $3 808 226), Lawrence Otto Klein (Sold 220 000 shares of value $25 006 712 ), Michael Tomsicek (Option Excercise at a value of $426 000), Michael Tomsicek (Sold 21 200 shares of value $1 887 083 ), Rodger Novak (Option Excercise at a value of $2 073 215), Rodger Novak (Sold 350 000 shares of value $30 325 597 ), Samarth Kulkarni (Option Excercise at a value of $130 818), Samarth Kulkarni (Sold 72 275 shares of value $9 215 040 ), Tony W. Ho (Option Excercise at a value of $398 012), Tony W. Ho (Sold 37 409 shares of value $4 521 617 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.